



RELMADA THERAPEUTICS, INC.
880 Third Avenue, 12th Floor
New York, New York 10022

August 19, 2020

VIA EDGAR

Division of Corporation Finance
Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549

Attention: Ms. Deanna Virginio

**Re: Relmada Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-245054**

Ladies and Gentlemen:

Relmada Therapeutics, Inc. (the "Company") hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of the effectiveness of the above-referenced Registration Statement so that such Registration Statement will become effective as of 4:00 p.m. Eastern time, Friday, August 21, 2020, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.

Very truly yours,

RELMADA THERAPEUTICS, INC.

By: /s/ Sergio Traversa
Name: Sergio Traversa
Title: Chief Executive Officer